inflammation and glp 1 GLP-1 Gut Health: Addressing Metabolic Dysfunction for Physicians Stories like this are why
Description
Recently, the GLP-1 RA semaglutide was reported to reduce cardiovascular events in ASCVD patients with overweight or obesity even in the absence of diabetes mellitus
The China Center for Drug Evaluation (CDE) announced that Shiling Pharma's semaglutide nasal spray has been approved for clinical trials for long-term weight management in adults (obese and overweight)
Liraglutide also suppressed NLRP3 transcription
Care and cost benefits of Castlights GLP-1 & Weight Management Program: GLP-1 medications have generated massive interest as powerful tools for weight loss and managing conditions like type 2 diabetes
It's transforming patient outcomesbut complex cases demand expert insight
